Phase 3 psilocybin and LSD data plus new FDA guidance fuel a depression boom—yet clinics still wrestle with dosing time, cost, access.
|Videos|September 25, 2020
Mindful Meditation
Author(s)John J. Miller, MD
Dr John Miller shows us one of his favorite topics to talk about and practice.
Advertisement
Dr Miller is medical director, Brain Health, Exeter, NH; editor in chief, Psychiatric Times®; staff psychiatrist, Seacoast Mental Health Center, Exeter, NH; consulting psychiatrist, Exeter Hospital, Exeter, NH; consulting psychiatrist, Insight Meditation Society, Barre, MA.
Advertisement
Related to this article
Ketamine, esketamine, and ECT can rapidly ease suicidal thoughts, but evidence for preventing attempts or deaths remains limited—see what’s proven.
Helus Pharma advances oral deuterated psilocin HLP003 for MDD, detailing new efficacy and safety analyses plus ongoing phase 3 PARADIGM trial updates.
Advertisement
Advertisement
Trending on Psychiatric Times
1
Defining Treatment-Resistant Depression In Adults
2
Interventional Options for TRD: ECT, TMS, and Esketamine
3
AI as a Task-Replacing Tool for Psychiatric Care: A Conversation With Christoph Correll, MD
4
Closing the Diagnostic Gap in Dementia With Blood-Based Biomarkers
5